Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04622774 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT04622774 is a Phase 1 study that has completed, run by ImmunoGen. The registered enrollment target is 56 participants.
The verdict
NCT04622774, a Phase 1 study, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.
Interventions
- DRUG IMGC936
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2023-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04622774
The ClinicalTrials.gov registry entry for NCT04622774 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMGC936 is the first listed.
NCT04622774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04622774 about?
NCT04622774 is a clinical study titled "First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors". This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.
What is the current status of trial NCT04622774?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2020-10-29. Estimated completion is 2023-12-28.
What interventions are being tested in trial NCT04622774?
The interventions under investigation include: IMGC936 (DRUG).
Who is sponsoring clinical trial NCT04622774?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.